0.04
-0.0056(-11.20%)
Currency In USD
Address
1901 West 47th Place
Kansas City, KS 66205
United States of America
Phone
913 942 2300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
N/A
| Name | Title | Pay | Year Born |
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, Chief Executive Officer & Chairman of the Board | 570,781 | 1975 |
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive Vice President & Chief Medical Officer | 244,792 | 1964 |
| Dr. Laurie A. Myers M.B.A., Ph.D. | Executive Vice President & Chief Operating Officer | 367,467 | 1957 |
| Thomas Dalton | Vice President of Investor & Public Relations | 0 | N/A |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive Vice President & Chief Science Officer | 0 | 1958 |
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.